Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AIMTNASDAQ:ALDRNASDAQ:CORTNASDAQ:INSMNASDAQ:QURE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/ACORTCorcept Therapeutics$22.78+2.6%$23.81$20.84▼$34.28$2.37B0.481.46 million shs27,596 shsINSMInsmed$24.89-0.1%$27.16$18.08▼$32.00$3.70B0.921.75 million shs20,699 shsQUREuniQure$4.57+0.7%$5.30$4.35▼$22.48$218.63M0.95958,195 shs13,934 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%ALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%CORTCorcept Therapeutics-1.20%-1.99%-10.26%+2.54%-0.09%INSMInsmed-3.45%+0.48%-7.77%-10.07%+28.72%QUREuniQure-0.44%-3.61%-14.66%-22.13%-76.53%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACORTCorcept Therapeutics4.778 of 5 stars3.51.00.04.52.53.33.1INSMInsmed4.0701 of 5 stars4.51.00.04.52.50.00.6QUREuniQure1.5327 of 5 stars3.42.00.00.00.62.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune TherapeuticsN/AN/AN/AN/AALDRAlder BiopharmaceuticalsN/AN/AN/AN/ACORTCorcept Therapeutics3.00Buy$39.3072.52% UpsideINSMInsmed3.00Buy$44.9280.46% UpsideQUREuniQure2.71Moderate Buy$32.00600.22% UpsideCurrent Analyst RatingsLatest ALDR, CORT, AIMT, INSM, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.004/23/2024INSMInsmedTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$48.004/11/2024INSMInsmedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $40.004/1/2024INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.003/4/2024QUREuniQureMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $7.003/1/2024QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.002/29/2024QUREuniQureThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$63.00 ➝ $8.002/27/2024INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.002/27/2024INSMInsmedUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$46.002/16/2024CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $42.002/15/2024INSMInsmedWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AALDRAlder Biopharmaceuticals$1.62M977.10N/AN/A$1.61 per share11.73CORTCorcept Therapeutics$482.38M4.92$0.97 per share23.47$4.92 per share4.63INSMInsmed$305.21M12.11N/AN/A($2.32) per share-10.73QUREuniQure$15.84M13.80N/AN/A$4.34 per share1.05Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AALDRAlder Biopharmaceuticals-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/ACORTCorcept Therapeutics$106.14M$0.9523.9817.13N/A21.86%21.98%17.89%5/1/2024 (Confirmed)INSMInsmed-$749.57M-$5.34N/AN/AN/A-245.59%N/A-53.34%5/2/2024 (Estimated)QUREuniQure-$308.48M-$6.48N/AN/AN/A-1,947.09%-99.31%-37.65%5/14/2024 (Estimated)Latest ALDR, CORT, AIMT, INSM, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024N/ACORTCorcept Therapeutics$0.18N/A-$0.18N/AN/AN/A 2/28/2024Q4 2023QUREuniQure-$1.54-$1.53+$0.01-$1.53$3.20 million$6.69 million2/22/202412/31/2023INSMInsmed-$1.13-$1.28-$0.15-$1.28$82.15 million$83.70 million 2/15/2024Q4 2023CORTCorcept Therapeutics$0.25$0.28+$0.03$0.28$129.27 million$135.41 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40ALDRAlder Biopharmaceuticals1.748.948.94CORTCorcept TherapeuticsN/A4.394.31INSMInsmedN/A4.123.75QUREuniQure0.498.858.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%ALDRAlder BiopharmaceuticalsN/ACORTCorcept Therapeutics93.61%INSMInsmedN/AQUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%ALDRAlder Biopharmaceuticals15.40%CORTCorcept Therapeutics19.80%INSMInsmed4.60%QUREuniQure4.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableALDRAlder Biopharmaceuticals20283.84 millionN/AOptionableCORTCorcept Therapeutics352104.08 million83.48 millionOptionableINSMInsmed373148.55 million141.72 millionOptionableQUREuniQure48047.84 million45.90 millionOptionableALDR, CORT, AIMT, INSM, and QURE HeadlinesSourceHeadlineuniQure (NASDAQ:QURE) Stock Price Crosses Below 200-Day Moving Average of $6.06americanbankingnews.com - April 19 at 4:58 AMUniQure (QURE) Reports Q4 Loss, Tops Revenue Estimateszacks.com - February 28 at 9:20 AMuniQure Announces 2023 Financial Results and Highlights Recent Company Progressglobenewswire.com - February 28 at 7:05 AMuniQure: The AMT-130 Readoutseekingalpha.com - July 17 at 1:47 PMMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureseekingalpha.com - May 22 at 5:38 PMuniQure: Financials And Pipeline Signal A Promising Outlook For Investorsseekingalpha.com - May 20 at 9:19 AMWhy Sunstar's unique M&A model is attractive to independent agencies - Insurance Businessinsurancebusinessmag.com - February 7 at 2:42 PMUnique new Greenville business hoping to lather up same success of other locations - WNCTwnct.com - February 7 at 2:42 PMNew: The Buffalo Gift Emporium is Expanding its Unique Selection of Gifts - Step Out Buffalostepoutbuffalo.com - February 7 at 2:42 PMMarshall fire victims with no renter's insurance face unique obstacles - The Colorado Suncoloradosun.com - February 7 at 2:42 PM'Chess on ice:' Curling classes give Olympic viewers chance to try unique sport in Grand Rapids - MLive.commlive.com - February 7 at 2:42 PMReview: Bittersweet, quirky 'Sapience' takes unique look at the hurdles of communication - The San Diego Union-Tribunesandiegouniontribune.com - February 7 at 2:42 PMHappy Rose Day: 5 Unique Rose Recipes You Can Make For Loved Ones - NDTV Foodfood.ndtv.com - February 7 at 9:41 AMUnique partnership solves UP bridge problem | News, Sports, Jobs - Escanaba Daily Pressdailypress.net - February 7 at 9:41 AMGeneva's Little Traveler to celebrate 100 years of unique shopping experience - Shaw Localshawlocal.com - February 7 at 9:41 AMPenguins duo unveils unique NIL deal with Austintown business - Warren Tribune Chronicletribtoday.com - February 7 at 9:41 AMDozens of unique vendors set up shop for Craft Fair - Marshalltown Times Republicantimesrepublican.com - February 7 at 9:41 AMUnique math class helps students build their futures - FOX 31 Denverkdvr.com - February 7 at 9:41 AMA DoSeum experience as unique as you and me - San Antonio Reportsanantonioreport.org - February 7 at 9:41 AMuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireglobenewswire.com - February 7 at 9:41 AMuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Diseasefinance.yahoo.com - February 7 at 9:41 AM'Cats on Mats' gives Bloomington adoption event a unique twist - HOI ABChoiabc.com - February 6 at 8:12 AMWould You Ride...These Crazy Unique Roller Coasters? - Theme Park Touristthemeparktourist.com - February 6 at 3:12 AM'Cats on Mats' gives Bloomington adoption event a unique twist - week.comweek.com - February 6 at 3:12 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackAll Headlines Company DescriptionsAimmune TherapeuticsNASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Alder BiopharmaceuticalsNASDAQ:ALDRAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.Corcept TherapeuticsNASDAQ:CORTCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.InsmedNASDAQ:INSMInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.uniQureNASDAQ:QUREuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.